On November 29, 2022 Kineta, Inc. ("Kineta" or the "Company"), a clinical-stage biotechnology company focused on developing next-generation immunotherapies to address cancer immune resistance, reported that the Company will present at the JMP Securities Hematology and Oncology Summit, a virtual investor event to be held from December 6-7, 2022 (Press release, Kineta, NOV 29, 2022, View Source;utm_medium=rss&utm_campaign=kineta-to-participate-in-jmp-securities-hematology-and-oncology-summit-2 [SID1234624552]). Shawn Iadonato, Ph.D., Kineta’s Chief Executive Officer, will present a corporate update and overview of KVA12123 (formerly referred to as KVA12.1), Kineta’s VISTA blocking immunotherapy. Kineta’s management team will also be available for virtual one-on-one meetings during the conference. For more information on the conference or to register, visit: View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A copy of the presentation will be available on the Kineta website under Events & Presentations after the conference on December 6, 2022: View Source

The summit will feature industry experts revisiting important takeaways from the recent European Society for Medical Oncology Immuno-Oncology Congress (ESMO) (Free ESMO Whitepaper) and Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting and offer the latest perspectives on developing therapeutics for solid tumors and hematological malignancies.